Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

the results of the first secondary endpoint, the statistical plan did not provide for a formal analysis of subsequent secondary endpoints(1).

Clinically meaningful differences were observed in time to SEGA progression. Of those patients receiving everolimus, 0% of patients (0 of 78) experienced disease progression (defined as increase in SEGA volume, worsening of non-target SEGAs, appearance of new lesions or new hydrocephalus), while 15% of patients (6 of 39) on placebo progressed(1).

Clinically meaningful differences were also observed in skin lesion response rate. A partial clinical response in skin lesions (corresponding to a 50% or greater improvement) was observed by Physician Global Assessment in 42% of patients (30 of 72) receiving everolimus, compared with 11% of patients (4 of 38) receiving placebo.  No complete responses were observed(1).

Additionally, a subset of patients (n=44) in this trial had angiomyolipomas, non-cancerous kidney tumors associated with TSC(1,6). As an exploratory endpoint, an angiomyolipoma response (corresponding to a volume reduction of 50% or greater) was observed in 53% of patients (16 of 30) receiving everolimus compared to 0% of patients (0 of 14) on placebo(1).

No adverse event (AE) leading to study drug discontinuation was observed during the study. The most common AEs in the everolimus versus the placebo arm (with an incidence of at least 20% in the everolimus arm) included mouth ulceration (32% vs. 5%), stomatitis (31% vs. 21%), convulsion (23% vs. 26%) and fever (22% vs. 15%). The most common Grade 3 AEs in the everolimus versus placebo arm (with an incidence of at least 5%) were stomatitis (8% vs. 3%), fever (6% vs. 0%) and convulsion (5% vs. 5%). One Grade 4 event of gastroenteritis was reported in the everolimus arm. Adverse events were mostly mild in severity (Grade 1/2) and were largely consistent with the known safety profile of everolimus. The most clinically notable AEs were infe
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Ore., Oct. 31, 2011 AgonOx today announced that ... MedImmune, the global biologics arm of AstraZeneca, to develop ... preclinical and clinical studies of this tumor-specific T-cell immunity ... very pleased to collaborate with MedImmune to advance our ...
... 31, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. ... the "Company"), a leading manufacturer of medical dressings, medical ... products in China, proudly announced today that Winner Industries ... subsidiaries, was ranked Top 500 Textile and Apparel Companies ...
Cached Medicine Technology:AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy 2AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy 3Winner Medical Ranked High by CNTAC 2Winner Medical Ranked High by CNTAC 3
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... physicians concerned about an increase in adolescents, marijuana use ... sigh of relief. According to a new study at ... data from states with and without medical marijuana laws, ... among adolescents. The study is published online in advance ... . , "Any time a state considers legalizing ...
(Date:4/23/2014)... also known as Ritalin, may prevent the depletion of ... , a journal of the Association for Psychological Science. ... diet or trying to focus attention on a boring ... one potential explanation for this difficulty: Exerting self-control for ... exert self-control effectively on subsequent tasks. , "It is ...
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:ADHD drug may help preserve our self-control resources 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... drug combination has the potential to double the life expectancy ... a cancer of the cells that make up the lining// ... ribs or around the abdominal organs. It differs from other ... exposure to asbestos, rather than by smoking. ,The condition ...
... body. When sweet corn is heated, its antioxidant content is ... healthy addition to one's diet.// There has always been a ... their nutritional content. According to new study, one loses some ... well gain more antioxidant power than you lose on cooking. ...
... Individuals who enjoy diets rich in meat, cheese and ... cancer of the esophagus and the stomach.The rates of ... esophagus//--have risen rapidly over the past 30 years. To ... of stomach and esophageal cancers and dietary factors, Dr. ...
... skin condition called contact dermatitis may benefit from ridding their ... to the results of a small study.// Individuals with contact ... in contact with substances they are allergic to. The reaction ... and many people may not realize foods can also trigger ...
... are more likely for Cesarean delivery, says Dr.Bell from Duke ... major causes of maternal mortality. //Pregnancy and obesity both make ... risk is doubled when the two conditions are combined. ... each woman's body mass index (BMI), a measurement of body ...
... researchers at the University of Chicago,restoring alcoholics have impaired ... of 50 male alcoholics detoxifying in hospital were compared ... hormone response and memory and problem solving. All participants ... mental arithmetic and having a hand placed in ice ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: